Liquid Phase Peptide Synthesis Market Segmentation by Product (Reagents, Equipment, Solvents, and Others); and by End-User (Pharmaceutical & Biotechnology Industry, Contract Development & Manufacturing Organizations, Academic & Research Institutes, and Others) – Global Demand Analysis and Opportunity Outlook 2030
Buy Now
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
September 2020: CSBio announced the release of CSBIO 2, the first and only fully automated peptide synthesizer. This release makes the peptides more accessible and helps enable drug discovery and commercialization of peptide therapeutics.
May 2020: Thermo Fisher Scientific announced a collaboration with MSAID GmbH to provide access to deep learning tools for discovery and targeted proteomics. This agreement helps in the development and commercialization of tools to open new insights in proteomic research.
The global liquid phase peptide synthesis market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The extensive deployment of liquid phase peptide synthesis in large-scale industries owing to its capability of producing a large number of high-quality peptides, are expected to fuel the growth of this market. Liquid phase peptide synthesis was the first method to be used for the generation of peptides in-vitro and is still commonly utilized for large-scale peptide synthesis required in end-user industries. It helps in performing convergent peptide synthesis in which separate peptides are synthesized and then are attached together to create larger peptides, which is why it is abundantly used for large-scale production of peptides. The growth of the market can also be attributed to factors such as the increasing use of peptides in pharmaceutical drug development, and treatment of various lifestyle disorders, such as, diabetes and obesity. According to the data collected from International Diabetes Federation, it is estimated that around 463 million people globally had diabetes in 2019, and by 2045, the count is projected to reach 700 million. Peptides have diverse biological characteristics such as high biological activity, high specificity & ample chemical space, relative ease of synthesis, easy availability, and low toxicity, which are further estimated to boost the market growth.
The global liquid phase peptide synthesis market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2022-2030. The extensive deployment of liquid phase peptide synthesis in large-scale industries owing to its capability of producing a large number of high-quality peptides, are expected to fuel the growth of this market. Liquid phase peptide synthesis was the first method to be used for the generation of peptides in-vitro and is still commonly utilized for large-scale peptide synthesis required in end-user industries. It helps in performing convergent peptide synthesis in which separate peptides are synthesized and then are attached together to create larger peptides, which is why it is abundantly used for large-scale production of peptides. The growth of the market can also be attributed to factors such as the increasing use of peptides in pharmaceutical drug development, and treatment of various lifestyle disorders, such as, diabetes and obesity. According to the data collected from International Diabetes Federation, it is estimated that around 463 million people globally had diabetes in 2019, and by 2045, the count is projected to reach 700 million. Peptides have diverse biological characteristics such as high biological activity, high specificity & ample chemical space, relative ease of synthesis, easy availability, and low toxicity, which are further estimated to boost the market growth.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the rising demand for novel antibody and protein-based drugs, and the easy & cost-effective procedure for liquid phase peptide synthesis in the region, backed by availability of cheap labour and raw materials. Moreover, the high prevalence of diseases, such as, diabetes in China and India is also estimated to boost the market growth. Around 60% of the population of Asia Pacific suffered from diabetes in 2019.
Furthermore, in 2030, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the favourable regulatory environment for early approval of peptide drugs, accompanied by the presence of advanced healthcare infrastructure in the region. According to the World Health Organization (WHO), 16.416 % of the GDP was spent on the healthcare sector in North America in 2018. Along with this, North America also has a high prevalence of chronic lifestyle disorders, which is also expected to boost the demand for peptides, which in turn, is expected to contribute to the market growth in the region.
Alternatively, the market in Europe is also anticipated to occupy a significant share in the liquid phase peptide synthesis market during the forecast period, on account of high use of liquid phase peptide synthesis for industrial purposes and the increased prevalence of obesity & diabetes in the region. As per the International Diabetes Federation Atlas, in 2019, around 59 million individuals in the age between 20-79 years had diabetes in Europe. Additionally, European region had the highest number of children and adolescents having Type-1 diabetes.
Get more information on this report: Download Sample PDF
The global liquid phase peptide synthesis market is further classified on the basis of region as follows:
Our in-depth analysis of the global liquid phase peptide synthesis market includes the following segments:
Ans: The extensive deployment of liquid phase peptide synthesis in large-scale industries and its capability of producing large number of high-quality peptides are the key factors driving market growth.
Ans: The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2022-2030.
Ans: The slow peptide production speed along with high labour requirement and dispersed regulations for therapeutic peptides are estimated to hamper the market growth.
Ans: The slow peptide production speed along with high labour requirement and dispersed regulations for therapeutic peptides are estimated to hamper the market growth.
Ans: The major players dominating the liquid phase peptide synthesis market are AAPPTec, LLC, CEM Corporation, Bachem Holding AG, Zen-Bio Inc, and CSBio, among others.
Ans: The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product, end-user, and by region.
Ans: With respect to end-user, the pharmaceutical & biotechnology industry segment is anticipated to hold the largest market share owing to growth in use of peptides for therapeutic development and ligation technologies.
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample
